ReviewEJNMMI research2026
Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting.
Review in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, we aimed to identify oncofetal antigens expressed in prostate cancer and systematically examine their potential role using theranostic approaches. Cell surface oncofetal antigens are expressed to a limited extent in adult cells and may be variably expressed in tumor cells. The fact that oncofetal proteins are not expressed in healthy cells minimizes the risk of systemic toxicity, especially when using targeted therapies. Cell surface oncofetal proteins identified in prostate cancer are CEACAM5, Trop-2 (TACSTD2), Glypican-3 (GPC3), ROR1 (NTRKR1), and 5T4 (TPBG). MAIN BODY: In accordance with PRISMA guidelines, we conducted a systematic review of peer-reviewed articles indexed in Scopus, PubMed and Web of Science databases until February 10, 2025. Studies evaluating the expression, biological role, and therapeutic relevance of cell surface oncofetal antigens in PC were included. Data extraction focused on their functional role in prostate cancer, associated radiopharmaceuticals, and clinical or preclinical therapeutic strategies. Five key oncofetal proteins: CEACAM5, Trop-2, ROR1, GPC3, and 5T4 have been consistently identified in the literature. These proteins have been associated with aggressive PC subtypes, including neuroendocrine and castration-resistant forms; and are linked to key signaling pathways such as Wnt/β-Catenin, EMT, and PI3K/AKT. Several investigational agents targeting these antigens, including antibody-drug conjugates (ADCs), CAR-T cells and radiolabeled imaging probes (e.g. 68Ga, 89Zr, 64Cu, 225Ac) are being developed and evaluated in both preclinical and early clinical settings.
conclusionCEACAM5, Trop-2, 5T4, GPC3, and ROR1 oncofetal proteins are variably expressed in advanced prostate cancer. Therapeutics and radiopharmaceutical imaging agents targeting these proteins are in development. Though provocative findings are apparent, considerable clinical research is needed to determine the value of targeting these proteins.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.